CD30

Product List

Creative Biolabs has successfully developed a variety of anti-CD30-related products to meet your exact project requirements.

Background

CD30, known as TNFRSF8, is a transmembrane protein expressed on the cell surface as a protein receptor with a 120 kDa molecular weight. Several studies have identified that CD30 plays a number of key roles in lymphocyte activation and survival, as well as in the regulation of immune responses. More importantly, CD30 is associated with the progression of various cancers, such as T-cell lymphoma, anaplastic large-cell lymphoma, and Hodgkin lymphoma. Nowadays, CD30 is a promising target for CART therapy.

Fig.1 Schematic representation of CD30 molecule in the intracellular signaling pathway.¹

Associated Diseases

• Hodgkin disease
• Large T/B cell lymphoma
• Embryonal carcinoma
• Hodgkin lymphomas
• CD30 positive cancers
• Others

Anti-CD30 CAR-T Services

Anti-CD30 CAR-T In Vitro Assays

Anti-CD30 CAR-T Proliferation Test

To assess the amplification potential of CART cells, Creative Biolabs successfully developed accurate and robust CART proliferation assay services to aid in CART development. We offer several approaches for global clients to perform CART proliferation assay smoothly, such as cell vitality real-time monitoring.

Fig.2 Total cell proliferation test of anti-CD30 CAR T-cells after CD30-CAR transduction (second-generation CD30-28z CAR and third-generation CD30-28BBz CAR).²

Anti-CD30 CAR-T Phenotype Characterization

To evaluate intracellular signal transduction in CART cells, we have developed various T cell subtype and phenotype analysis services to study T cell subpopulation distribution, T cell activity, and exhaustion function by flow cytometry.

Fig.3 Phenotype analysis of second-generation and third-generation Anti-CD30 CAR T-cells by flow cytometry.²

Anti-CD30 CAR-T Expression Test

To detect antigen-specific CAR expression, Creative Biolabs provides comprehensive approaches (such as qPCR, flow cytometry, WB), as well as extensive CAR detection reagents (anti-Fab antibodies, anti-G4S linker antibodies) to support customers' special needs.

Fig.4 Flow cytometry analysis of CD30 CAR expression on second-generation and third-generation Anti-CD30 CAR T-cells after CD30-CAR lentivirus transduction.²

Anti-CD30 CAR-T Cytokine Release Test

To help global clients speed CART development, Creative Biolabs is committed to providing a comprehensive range of cytokine analysis services by various methods, such as ELISA, ELISPOT, and multiplex cytokine array.

Fig.5 Cytokine production analysis (IFNγ and IL-6) in second-generation and third-generation Anti-CD30 CAR T-cells co-cultured with CD30+L428 cells or CD30-Raji cells.²

Anti-CD30 CAR-T In Vitro Cytotoxicity Assay

In the CART development, CART anti-tumor activity validation is a necessary step to detect the effectiveness of CART cells. Leveraging our advanced technology platforms, we offer highly sensitive CAR-T cell cytotoxicity assay services to help global clients validate the targeted effectiveness of CAR-T products.

Fig.6 Cytotoxicity of second-generation and third-generation CD30 CAR T-cells against 3 different tumor target cells at indicated E:T ratio.²

Anti-CD30 CAR-T In Vivo Assays

Efficacy Test of Anti-CD30 CAR-T

Meanwhile, Creative Biolabs specializes in providing extensive mouse models and comprehensive in vivo anti-tumor assay services to evaluate the efficacy of CAR-T cells.

Fig.7 In vivo anti-tumor evaluation of second-generation and third-generation CD30 CAR-T in the CD30+L428 xenograft model. (Zhang, et al., 2022).²

Toxicity Evaluation Anti-CD30 CAR-T

CAR-T cell therapy-associated toxicity remains challenging in CART studies. The evaluation of toxicity and safety has been a crucial step in CART development. At Creative Biolabs, we provide several robust in vivo assay services for toxicity evaluation and safety assessment of CAR-T cell therapy, including on-target, and off-target toxicity studies, and CRS management.

References

1. Dumitru, Adrian Vasile.; et al. "The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment." Cells 12.13 (2023): 1783.
2. Zhang, Shangkun.; et al. "The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity." Scientific reports 12.1 (2022): 10488.